Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine

• Published in: Vaccine Vol. 23; no. 38; pp. 4678 - 4684
• Main Authors: Ghendon, Y.Z., Markushin, S.G., Akopova, I.I., Koptiaeva, I.B., Nechaeva, E.A., Mazurkova, L.A., Radaeva, I.F., Kolokoltseva, T.D.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 07-09-2005; Elsevier Limited
• Subjects: Adaptation, Physiological; Amino acids; Animals; Cell culture; Cold Temperature; Fermenter; Influenza; Influenza A virus - genetics; Influenza A virus - growth & development; Influenza Vaccines - immunology; Influenza virus; Live vaccines; MDCK cells; Mutation; Pandemics; Reassortant Viruses - immunology; Reassortant Viruses - physiology; Temperature; Tumor Cells, Cultured - virology; Vaccines; Vaccines, Attenuated - immunology; Fermenter; Live vaccines; MDCK cells; Influenza
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2005.04.039

Optimal conditions are determined for growing cold-adapted reassortant strains of a live influenza vaccine in MDCK cell line cultivated in a fermenter with a serum-free medium and microcarriers. The studied MDCK cell line meet all national and WHO requirements for the finite cell lines used for the production of biological preparations. CA reassortant vaccine strains grown in such conditions which fully preserve its mutations and the mutations lead to amino acid substitution in all genome segments of the studied CA reassortants. Under optimal cultivation conditions, the output of a monovalent live CA influenza vaccine in a 10-l fermenter may reach 100,000 doses.